Sotac Pharmaceuticals Share Price & Earnings Call Analysis
- Market cap
- ₹136 Cr
- P/E
- 23.91
- ROE
- 10.13%
- PEG
- 0.78
- Price to sales
- 1.34
- Debt to equity
- 0.64
- 52W high / low
- ₹152 / ₹100
- Sales growth (5Y)
- 15.59%
- EBITDA margin
- 17.75%
- Net profit margin
- 6.15%
- Promoter holding
- 72.85%
- Sales (last year)
- ₹101 Cr
Incorporated in 2015, Sotac Pharmaceuticals Ltd manufactures and sells a wide range of pharmaceutical products[1]
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹480 Cr | 19.1 | |
| 2 | 40%+ | Up 0–2% | ₹212 Cr | 16.1 | |
| 3 | 40%+ | Flat | ₹17,925 Cr | — | |
| 4 | 40%+ | Flat | ₹5,223 Cr | 39.1 | |
| 5 | 40%+ | Flat | ₹4,268 Cr | — | |
| 6 | 40%+ | Flat | ₹40 Cr | — |
Sign up free to see every company in the sector ranking and track Sotac Pharmaceuticals.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Sotac Pharmaceuticals
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Sotac Pharmaceuticals
Quarterly Results
Quarter-by-quarter operating performance
Financials of Sotac Pharmaceuticals
Profit & Loss
Annual income statement trend
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales + | 29 | 49 | 77 | 104 | 97 | 101 |
| Expenses + | 27 | 47 | 70 | 95 | 83 | 83 |
| Operating Profit | 2 | 1 | 7 | 9 | 14 | 18 |
| OPM % | 7% | 3% | 10% | 8% | 14% | 18% |
| Other Income + | 0 | 0 | 1 | 0 | 4 | 0 |
| Interest | 0 | 1 | 2 | 2 | 3 | 4 |
| Depreciation | 1 | 3 | 2 | 3 | 4 | 5 |
| Profit before tax | 0 | -2 | 4 | 4 | 11 | 9 |
| Tax % | 75% | 15% | 42% | 10% | 17% | 28% |
| Net Profit + | 0 | -2 | 2 | 4 | 9 | 6 |
| EPS in Rs | 0.39 | -10.30 | 3.58 | 3.87 | 7.27 | 5.22 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Sotac Pharmaceuticals
Balance Sheet
Capital structure and asset base
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 8 | 11 | 11 | 11 |
| Reserves | 1 | 0 | 11 | 34 | 42 | 48 |
| Borrowings + | 13 | 17 | 22 | 25 | 44 | 38 |
| Other Liabilities + | 14 | 15 | 32 | 35 | 27 | 37 |
| Total Liabilities | 30 | 35 | 74 | 105 | 124 | 133 |
| Fixed Assets + | 16 | 17 | 26 | 36 | 49 | 50 |
| CWIP | 0 | 0 | 0 | 5 | 0 | 2 |
| Investments | 0 | 0 | 0 | 2 | 4 | 3 |
| Other Assets + | 14 | 18 | 48 | 63 | 72 | 79 |
| Total Assets | 30 | 35 | 74 | 105 | 124 | 133 |
Financials of Sotac Pharmaceuticals
Cash Flows
Operating, investing and financing cash movement
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0 | -0 | 8 | -16 | -4 | 17 |
| Cash from Investing Activity + | -12 | -3 | -12 | -20 | -14 | -7 |
| Cash from Financing Activity + | 11 | 3 | 13 | 29 | 16 | -10 |
| Net Cash Flow | -0 | -0 | 10 | -6 | -2 | -0 |
| Free Cash Flow | -10 | -3 | 0 | -34 | -16 | 9 |
| CFO/OP | 17% | 8% | 134% | -168% | -26% | 106% |
Financials of Sotac Pharmaceuticals
Ratios
Working capital efficiency and return ratios
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 89 | 44 | 70 | 92 | 128 | 119 |
| Inventory Days | 40 | 45 | 87 | 83 | 108 | 153 |
| Days Payable | 194 | 121 | 162 | 132 | 101 | 154 |
| Cash Conversion Cycle | -66 | -32 | -5 | 43 | 136 | 118 |
| Working Capital Days | -79 | -44 | -40 | 47 | 63 | 65 |
| ROCE % | -5% | 10% | 15% | 13% |
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Anthem Bioscienc (Q2 FY27)
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc
- Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
- Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest
- Kopran (Q2 FY27)
9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.